atad1b Antibody

What is ARID1B and why is it significant in research?

ARID1B encodes the AT-rich interactive domain-containing protein 1B (also known as BAF250B), a critical subunit of the BRG1/BRM-associated factor (BAF) complex. This chromatin remodeling complex plays essential roles in regulating organ development, tissue homeostasis, and disease mechanisms . ARID1B is particularly significant because haploinsufficiency of this gene causes Coffin-Siris syndrome characterized by developmental delay, facial dysmorphism, and intellectual disability. It is also a frequent cause of autism spectrum disorder (ASD) and emotional disturbances, making it a high-priority target for neurodevelopmental research .

What are the known alternative names and structural characteristics of ARID1B protein?

ARID1B protein may also be referred to as BAF250B, 6A3-5, BRIGHT, CSS1, AT-rich interactive domain-containing protein 1B, and ARID domain-containing protein 1B in scientific literature. Structurally, the protein has a molecular mass of approximately 236.1 kilodaltons. Understanding these alternative nomenclatures is essential when searching literature or selecting appropriate antibodies for specific experimental applications .

What species orthologs of ARID1B are available for cross-reactivity studies?

Based on gene sequence conservation, ARID1B antibodies may cross-react with orthologs from canine, porcine, monkey, mouse, and rat species. This cross-reactivity information is crucial when designing comparative studies or when selecting appropriate animal models for ARID1B-related research. Researchers should verify specific antibody cross-reactivity through validation studies before proceeding with experiments using non-human samples .

What criteria should researchers consider when selecting an ARID1B antibody for specific applications?

When selecting an ARID1B antibody, researchers should evaluate several technical parameters:

• Application compatibility: Confirm the antibody has been validated for your specific application (Western blot, immunohistochemistry, immunofluorescence, flow cytometry)

• Species reactivity: Ensure compatibility with your experimental model organism

• Epitope location: Consider whether N-terminal, C-terminal, or internal epitopes are more appropriate for your research question

• Clonality: Monoclonal antibodies provide higher specificity while polyclonal antibodies might offer stronger signals

• Validation data: Review published validation data including western blot images showing expected band size (236.1 kDa)

• Citation record: Consider antibodies with successful use in peer-reviewed publications

Pre-experimental validation using positive and negative controls is always recommended regardless of supplier claims .

How should researchers validate ARID1B antibody specificity before experimental use?

A methodical validation approach for ARID1B antibodies should include:

• Positive control testing using tissues or cells known to express ARID1B (e.g., neural progenitors, mesenchymal stem cells)

• Negative control testing using ARID1B knockout/knockdown cells or tissues

• Western blot analysis confirming single band at expected molecular weight (236.1 kDa)

• Peptide competition assay to confirm epitope specificity

• Comparison of staining patterns across multiple antibodies targeting different ARID1B epitopes

• Cross-validation using orthogonal techniques (e.g., confirming protein expression with mRNA expression)

This systematic validation ensures experimental results can be confidently attributed to ARID1B detection rather than non-specific binding .

What are the optimal conditions for Western blot detection of ARID1B?

For optimal Western blot detection of ARID1B protein (236.1 kDa), researchers should consider the following methodological approach:

• Sample preparation: Use RIPA or NP-40 buffer with protease inhibitors and phosphatase inhibitors

• Gel selection: Use low percentage (6-8%) SDS-PAGE gels due to the high molecular weight of ARID1B

• Transfer conditions: Employ wet transfer at low voltage (30V) overnight at 4°C for efficient transfer of large proteins

• Blocking: 5% non-fat dry milk or BSA in TBST for 1-2 hours at room temperature

• Primary antibody incubation: 1:500-1:1000 dilution overnight at 4°C

• Detection system: HRP-conjugated secondary antibody with enhanced chemiluminescence

• Exposure time: Begin with longer exposures (1-5 minutes) due to potentially low expression levels

These optimized conditions address the challenges associated with detecting large molecular weight proteins like ARID1B .

How should researchers approach ARID1B immunohistochemistry in brain tissue samples?

For effective immunohistochemical detection of ARID1B in brain tissue, follow these methodological guidelines:

• Fixation: Use 4% paraformaldehyde for 24-48 hours; avoid over-fixation which can mask epitopes

• Antigen retrieval: Heat-mediated antigen retrieval in citrate buffer (pH 6.0) for 20 minutes is typically required

• Blocking: Use 10% normal serum (from secondary antibody host species) with 0.3% Triton X-100

• Primary antibody: Incubate with validated ARID1B antibody (1:100-1:200 dilution) for 48 hours at 4°C

• Secondary detection: Use biotinylated secondary antibody with avidin-biotin complex for signal amplification

• Controls: Include ARID1B knockout tissue or primary antibody omission controls

• Counterstaining: Light hematoxylin counterstaining helps visualize tissue architecture

This approach has been successfully used in studies examining ARID1B expression in neural progenitors and mature neurons .

How can researchers effectively use ARID1B antibodies to study chromatin remodeling mechanisms?

To investigate ARID1B's role in chromatin remodeling:

• Chromatin Immunoprecipitation (ChIP):

  • Cross-link cells with 1% formaldehyde for 10 minutes

  • Sonicate chromatin to 200-500bp fragments

  • Immunoprecipitate with validated ARID1B antibody

  • Analyze by qPCR or sequencing to identify ARID1B binding sites

• Co-Immunoprecipitation (Co-IP) for BAF complex interactions:

  • Use cell lysates prepared with non-denaturing buffers

  • Immunoprecipitate with ARID1B antibody

  • Western blot for other BAF complex components (BRG1, BAF155, BAF170)

• Proximity Ligation Assay (PLA):

  • Use two antibodies targeting different BAF complex components

  • Visualize protein-protein interactions in situ

  • Quantify interaction signals across experimental conditions

These approaches can reveal ARID1B's association with specific genomic regions and protein complexes, providing insights into its regulatory mechanisms in chromatin remodeling .

What experimental strategies can address the role of ARID1B in mesenchymal stem cell maintenance?

Based on recent findings about ARID1B's role in mesenchymal stem cell quiescence, researchers should consider these experimental approaches:

• Lineage tracing combined with ARID1B immunostaining:

  • Use GLI1-CreERT2 system for MSC lineage marking

  • Co-immunostain for ARID1B and quiescence markers (e.g., p27Kip1)

  • Analyze spatial distribution in stem cell niches

• Single-cell analysis after ARID1B perturbation:

  • Perform scRNA-seq and scATAC-seq on control and ARID1B-deficient MSCs

  • Compare chromatin accessibility at key regulatory regions

  • Identify transcriptional programs affected by ARID1B loss

• Mechanistic pathway analysis:

  • Immunoblot for p-ERK and Activin signaling components

  • Perform rescue experiments using inhibitors of ERK phosphorylation

  • Monitor Bcl11b expression levels as downstream target

These approaches can help elucidate ARID1B's role in maintaining MSC quiescence through epigenetic regulation of key signaling pathways .

How should researchers troubleshoot inconsistent or weak ARID1B antibody signals?

When encountering weak or inconsistent ARID1B detection, systematically troubleshoot using this approach:

• Protein extraction optimization:

  • Test alternative lysis buffers (NP-40, RIPA, or specialized nuclear extraction buffers)

  • Include phosphatase and protease inhibitors

  • Avoid repeated freeze-thaw cycles

• Epitope accessibility issues:

  • Try multiple antibodies targeting different epitopes

  • Optimize antigen retrieval conditions (time, temperature, buffer pH)

  • Consider alternative fixation protocols

• Signal enhancement strategies:

  • Increase antibody concentration or incubation time

  • Use signal amplification systems (TSA for IHC/IF, enhanced chemiluminescence for WB)

  • Reduce washing stringency while maintaining specificity

• Sample-specific considerations:

  • Verify ARID1B expression levels in your specific sample type

  • Consider developmental timing (expression may vary during development)

  • Check for potential post-translational modifications affecting epitope recognition

This systematic approach helps identify and address technical factors affecting ARID1B detection .

How can researchers reconcile conflicting data regarding ARID1B expression patterns?

When confronted with conflicting ARID1B expression data across studies:

• Methodological comparison:

  • Compare antibodies used (epitope differences, validation methods)

  • Assess fixation and antigen retrieval protocols

  • Evaluate detection systems and sensitivity thresholds

• Biological variables analysis:

  • Consider developmental stage differences (ARID1B expression changes during development)

  • Evaluate cell/tissue type specificity (expression varies across cell types)

  • Assess species differences if comparing across model organisms

• Context-dependent regulation:

  • Investigate pathological conditions altering expression

  • Consider transcriptional vs. post-transcriptional regulation

  • Examine subcellular localization differences

• Quantification approach:

  • Compare relative vs. absolute quantification methods

  • Assess normalization strategies

  • Evaluate statistical approaches used

This analytical framework helps contextualize apparently conflicting results and identify biological versus technical sources of variation .

What are the emerging applications of ARID1B antibodies in neurodevelopmental disorder research?

Recent advances in ARID1B research highlight several promising applications:

• Patient-derived models:

  • Detecting ARID1B expression in iPSC-derived neurons from Coffin-Siris syndrome patients

  • Monitoring ARID1B levels during neuronal differentiation protocols

  • Assessing BAF complex composition in patient-derived cells

• Therapeutic screening:

  • Evaluating GABA receptor modulators as potential treatments

  • Monitoring ARID1B-regulated target genes after compound treatment

  • Assessing chromatin accessibility changes in response to interventions

• Circuit-level analysis:

  • Examining ARID1B expression in specific neuronal populations (particularly Pvalb-expressing interneurons)

  • Correlating ARID1B levels with Wnt/β-catenin signaling in ventral telencephalon

  • Investigating ARID1B in excitatory/inhibitory balance regulation

These applications leverage ARID1B antibodies to advance understanding of pathological mechanisms and potential therapeutic approaches for ARID1B-related neurodevelopmental disorders .

How can machine learning approaches enhance ARID1B antibody-based research?

Emerging computational approaches offer new opportunities for ARID1B antibody applications:

• Epitope prediction and antibody design:

  • Computational prediction of optimal ARID1B epitopes

  • Structure-based antibody engineering for improved specificity

  • In silico screening of antibody candidates

• Image analysis automation:

  • Deep learning algorithms for quantifying ARID1B immunostaining patterns

  • Automated colocalization analysis with other BAF complex components

  • Computer vision approaches for high-throughput screening

• Multi-omics integration:

  • Correlating antibody-based protein detection with transcriptomics/epigenomics

  • Predicting functional consequences of ARID1B variants

  • Building regulatory network models centered on ARID1B

• Active learning for optimizing experimental design:

  • Reducing experimental iterations through predictive modeling

  • Optimizing antibody-antigen binding prediction

  • Improving out-of-distribution performance in binding predictions

These computational approaches can enhance experimental efficiency and extract deeper insights from ARID1B antibody-based research .

What are the comparative advantages of different application methods for ARID1B antibodies?

This comparison helps researchers select the most appropriate method based on their specific experimental questions and sample constraints .

How does ARID1B expression and function compare across different cell and tissue types?

This tissue-specific information guides researchers in experimental design, selection of appropriate controls, and interpretation of results in a context-specific manner .